These developments underline a move away from aggressive surgical cytoreduction towards more biologically-informed, less invasive management and earlier detection in high-risk cohorts, while embracing biomarker-driven systemic and intrapleural therapies to optimize outcomes. Future research should prioritize mesothelioma-specific trials to define the role and sequencing of perioperative immunotherapy and novel agents. AI tools may assist disease diagnosis, prognostication, and treatment selection.
Tan et al. (Wed,) studied this question.